🔗 Share this article

As America proceeds with sweeping changes to its immunization guidelines, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by questioning Covid vaccines during the global health crisis and has focused upon potential deaths after COVID-19 vaccination in her recent tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Vaccine Program

Agency leaders were set to reveal major revisions to the childhood vaccine schedule recently, bringing the US with Denmark’s vaccine program, according to reports – a major change that would put the US out of step with a large portion of the world with little proof for public health gain. This reveal has been delayed until the coming year.

In place of Vinay Prasad, Høeg is set to speak at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth individual to run the division this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for halting certain childhood vaccine recommendations in the US so as to align more similar to Denmark, a country with comprehensive healthcare and a population approximately the size of Wisconsin’s.

In her initial statements, she has kept her attention on immunizations – traditionally the domain of Dr. Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Concerns Over Background

Høeg has little discernible background in drug development, oversight or administrative roles, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the CDER, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in managing a major agency. She has no expertise in pharmaceutical oversight.”

Previous heads of the center would “grasp regulatory frameworks and the underlying principles of drug development”, noted Janet Woodcock. “Frankly, she lacks the sort of resume that former directors who led the center have had.”

CDER has an immense workload at the agency, she pointed out.

“The public just pays attention on the new drug program, but the off-patent medication office approves thousands of generic medications. There is also a biosimilars division, over-the-counter program and more, and every single one need to be supervised,” Woodcock noted. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial management component to the position, which manages more than 5,000 employees. “It’s a enormous management job, if you execute it properly,” the former official added.

Agency Reaction and Disputed Initiatives

When asked about questions about Dr. Høeg's fitness for the role and whether this selection indicates increased cooperation among agency officials on vaccines, a press secretary said that the “questions stem from incorrect premises”.

“Her resume aligns with the functions of her role,” the representative explained, noting the months Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the agency head's new priority voucher program, a disputed expedited medication authorization process that reportedly troubled her predecessors. “By what process are these medications being selected for this voucher program? Who makes the decisions?” Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he stated, “the FDA looks to be trending towards laxer regulations of pharmaceuticals, except for vaccines.”

Documented History on Immunizations

With immunizations, Dr. Høeg has a more established, if problematic, track record, critics said. She authored a study using unverified crowd-sourced reports to determine the frequency of heart inflammation after COVID-19 immunization. She consulted for the state of Florida top health official Joseph Ladapo, who was said to have modified findings to indicate Covid vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the current government featured revising regulations for new vaccines and halting “optional” vaccines, she remarked following the vote on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of preventing adolescent males from receiving Covid vaccinations.

“She is an all-around ideologue who begins with her preconceived notions and works backwards to retrofit the data in a very deceptive, dishonest way,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other contrarians, {like|